SY-2101: An Approach to Dramatically Reduce the Treatment Burden for APL Patients
SY-2101 is a novel oral form of arsenic trioxide (ATO) in development for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML) that is caused by a fusion of the RARA and PML genes. We are currently conducting a Phase 1 clinical trial of SY-2101 in newly diagnosed APL patients that is designed to confirm the dose for a future registration-enabling study.